I9
I9DN.F Arbutus Biopharma Corp
- Market cap
- EUR 555M
- P/E
- 3.8x
- P/B
- 6.77x
- ROE
- 127.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is I9DN.F undervalued?
Graham numberI9DN.F trades 6.5% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Arbutus Biopharma Corp fundamental analysis
No fundamental analysis for Arbutus Biopharma Corp yet.
Arbutus Biopharma Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Arbutus Biopharma Corp
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has …
Full company profileArbutus Biopharma Corp financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Arbutus Biopharma Corp annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.49M | 10.7M | 5.95M | 6.01M | 6.91M | 11.0M | 39.0M | 18.1M | 6.17M | 14.1M | 360M |
| Gross Profit | -59.8M | -52.0M | -52.0M | -51.6M | -40.6M | - | - | - | - | - | - |
| Operating Income | -100M | -70.1M | -70.2M | -71.3M | -57.3M | -71.7M | -63.2M | -78.0M | -70.0M | -27.1M | 327M |
| EBITDA | - | -106M | -58.9M | -162M | -57.8M | -71.6M | -63.3M | -71.0M | -68.4M | -33.0M | 329M |
| Net Income | -384M | -84.4M | -57.1M | -154M | -63.7M | -76.2M | -69.5M | -72.8M | -69.9M | -33.5M | 329M |
| EPS | - | -1.53 | -1.01 | -2.37 | -0.70 | -0.53 | -0.44 | -0.43 | -0.37 | -0.17 | 1.67 |
| Balance Sheet | |||||||||||
| Total Assets | 276M | 237M | 228M | 106M | 137M | 204M | 195M | 144M | 132M | 94.6M | 274M |
| Total Liabilities | 72.9M | 54.7M | 27.7M | 32.8M | 35.1M | 35.0M | 58.6M | 38.4M | 34.3M | 18.0M | 15.3M |
| Shareholders' Equity | 203M | 182M | 200M | 72.7M | 102M | 169M | 137M | 106M | 97.4M | 76.6M | 259M |
| Cash & Short-term Investments | 23.4M | 54.3M | 36.9M | 31.8M | 52.3M | 109M | 30.8M | 26.3M | 36.3M | 18.0M | 19.2M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -57.9M | -48.6M | -67.9M | -71.0M | -51.4M | -67.5M | -35.4M | -85.9M | -64.9M | -39.6M | -28.3M |
| Capital Expenditure | 4.00M | 7.26M | 1.14M | 589K | 229K | 809K | 512K | 1.01M | 182K | 0.00 | 0.00 |
| Free Cash Flow | - | -55.9M | -69.0M | -71.6M | -51.7M | -68.3M | -35.4M | -86.9M | -65.0M | -39.6M | -28.3M |
| Ratios | |||||||||||
| ROE | -189.2% | -46.3% | -28.5% | -211.3% | -62.5% | -45.0% | -50.8% | -68.7% | -71.8% | -43.7% | 127.2% |
| ROA | -139.2% | -35.6% | -25.0% | -145.7% | -46.5% | -37.3% | -35.5% | -50.4% | -53.1% | -35.4% | 120.1% |
| Net Profit Margin | -25,765.5% | -788.9% | -959.8% | -2,557.4% | -922.0% | -693.9% | -178.0% | -401.6% | -1,133.0% | -237.9% | 91.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Arbutus Biopharma Corp dividends
Arbutus Biopharma Corp has not paid dividends in the last 9 fiscal years.
Who owns Arbutus Biopharma Corp
- Insiders 20.57%
- Institutions 79.43%
- Public & others 0.00%
- Shares outstanding 153M
- Free float 117M
Arbutus Biopharma Corp company profile
- Company name
- Arbutus Biopharma Corp
- Ticker
- I9DN.F
- ISIN
- CA03879J1003
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 19
- Fiscal year end
- December
- Address
- 701 Veterans Circle, Warminster, PA, United States, 18974
- Phone
- 267 469 0914
- Website
- arbutusbio.com
About Arbutus Biopharma Corp
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Arbutus Biopharma Corp management
4- Ms. Lindsay Androski J.D., M.B.A.President, CEO & Chairman · born 1977
- Mr. Tuan NguyenChief Financial Officer · born 1976
- Mr. Andrew J. SungGeneral Counsel
- Mr. R. Hector Mackay-Dunn B.A., J.D., L.L.B., Q.C.Corporate Secretary · born 1951